Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹721.1 Cr
verified against source
Revenue YoY
6%
reported change
EBITDA
₹96.6 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Aarti Drugs reported Q4 FY26 consolidated revenue of ₹721.1 crore (+6% YoY) and EBITDA of ₹96.6 crore (13.4% margin). PAT declined 12% YoY to ₹55.3 crore due to elevated costs and ramp-up expenses. The methylamine plant achieved ~40% utilization in Q4, targeting 55-60% in Q1 FY27. Formulation revenue surged 41% YoY to ₹91.3 crore, driven by export growth. Management guided for 8-10% volume growth and 100-200 bps EBITDA margin improvement in FY27, contingent on stable crude prices. Key risks include sustained high crude impacting antibiotic demand and delayed salicylic acid turnaround.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects to cross 55-60% utilization in the June quarter, with a path to >70% within a year.
- Management targets 8-10% volume growth, with internal aspirations of 10-15%, supported by new capacities.
- Targeting EBITDA margins between 13.5% and 14% for FY27, assuming stable crude prices; without war, target was 14-14.5%.
- Planned capex for brownfield expansions and formulation capacity, including oncology, over the next 2-3 years.
Risks flagged
- If crude remains above $110-120, domestic antibiotic demand may decline due to price sensitivity, impacting volumes.
- Salicylic acid production remains shut due to equipment delays and variable losses; restart depends on successful installation and testing.
- Higher utilization of the methylamine plant requires commensurate metformin production expansion, which is still underway.
- West Asia war caused ammonia shortages in March; further escalation could disrupt key raw material availability.
Key quotes
- We are expecting that in June quarter we should easily cross around 55 to 60% of utilization for that plant and within a year's time we believe that we should be operating upwards of 70% utilization of the methylamide plants.
- The longer the war stretches, the positive variance would be more.
- We would still like to target EBITDA margins anywhere between 13 and a half to 14% for this FY27.
Research modules